Some additional thoughts on time-varying treatment effects in breast cancer

Journal of Clinical Oncology

Volumn 29, Issue 33, 2011, Pages 4469-4470

  Dignam, James J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; TAMOXIFEN;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER RISK; HAZARD ASSESSMENT; HORMONAL THERAPY; LETTER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENCE RISK; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME;

BREAST NEOPLASMS; FEMALE; HUMANS;

EID: 81755162808     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.37.8166     Document Type: Letter

References (16)

1. Jatoi I, Anderson WF, Jeong JH, et al.: Breast cancer adjuvant therapy: Time to consider its time-dependent effects. J Clin Oncol 29:2301-2304, 2011
2. Saphner T, Tormey DC, Gray R: Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14:2738-2746, 1996 (Pubitemid 26329660)
3. Hilsenbeck SG, Ravdin PM, de Moor CA, et al.: Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat 52:227-237, 1998 (Pubitemid 29056098)
4. Hess KR, Pusztai L, Buzdar AU, et al.: Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat 78:105-118, 2003 (Pubitemid 36223023)
5. Dignam JJ, Dukic V, Anderson SJ, et al.: Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer. Breast Cancer Res Treat 116:595-602, 2009
6. Lin NU, Winer EP: Advances in adjuvant endocrine therapy for postmenopausal women. J Clin Oncol 26:798-805, 2008 (Pubitemid 351264393)
7. Tusquets Trías de Bes I, Tormo SS, Mestres JA: Start strong or switch? Adjuvant endocrine strategies for postmenopausal women with hormonesensitive breast cancer. Biomed Pharmacother 63:1-10, 2009
8. Aalen O, Gjessing H: Understanding the shape of the hazard rate: A process point of view. Stat Sci 16:1-22, 2001 (Pubitemid 33632844)
9. Berry D: Breast cancer heterogeneity may explain peaks in recurrence. Int J Surg 3:287, 2005
10. Bryant J, Fisher B, Gündüz N, et al.: S-phase fraction combined with other patient and tumor characteristics for the prognosis of node-negative, estrogenreceptor- positive breast cancer. Breast Cancer Res Treat 51:239-253, 1997 (Pubitemid 29054557)
11. Berry DA, Cirrincione C, Henderson IC, et al.: Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295:1658-1667, 2006
12. Dukić V, Dignam J: Bayesian hierarchical multiresolution model for the study of time-dependent patterns of failure in early stage breast cancer. Bayesian Analysis 2:591-610, 2007
13. Gilbert PB, Wei LJ, Kosorok MR, et al.: Simultaneous inferences on the contrast of two hazard functions with censored observations. Biometrics 58:773- 780, 2002
14. Wei G, Schaubel DE: Estimating cumulative treatment effects in the presence of nonproportional hazards. Biometrics 64:724-732, 2008
15. Lin Chin-Yu, Kosorok MR: A general class of function-indexed nonparametric tests for survival analysis. Ann Statist 27:1722-1744, 1999
16. Eng KH, Kosorok MR: A sample size formula for the supremum log-rank statistic. Biometrics 61:86-91, 2005 (Pubitemid 40380967)